Prof Eric Van Cutsem, MD, PhD - Putting a Personalized Colorectal Cancer Treatment Algorithm Into Practice: Navigating Practicalities in the Era of Molecularly Defined Care

Go online to PeerView.com/JEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discuss clinical decision-making, current guideline recommendations for biomarker testing, and the potential utility of such testing in improving disease management and clinical outcomes in patients with colorectal cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest clinical data informing the use of available targeted, immune, and chemotherapeutic agents in upfront and recurrent settings for patients with advanced/metastatic CRC, Summarize key clinical trial data on emerging agents and combinations for patients with advanced/metastatic CRC, and consider their utility in improving disease management and clinical outcomes, Apply current guideline recommendations for biomarker testing—including testing for RAS and BRAF mutations, MSI/MMR status, HER2 overexpression, and NTRK fusions—to guide the selection of targeted and immune-based therapies for patients with advanced/metastatic CRC, Implement personalized treatment algorithms for patients with advanced/metastatic CRC—including the consideration of clinical trial enrollment—based on clinical evidence, practice guidelines, and collaboration with members of the care team.